Penetration enhancers for topical drug delivery to the ocular posterior segment: a systematic Review

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéuticagl
dc.contributor.authorThareja, Abhinav
dc.contributor.authorHughes, Helen
dc.contributor.authorÁlvarez Lorenzo, Carmen
dc.contributor.authorHakkarainen, Jenni J.
dc.contributor.authorAhmed, Zubair
dc.date.accessioned2023-03-27T11:11:52Z
dc.date.available2023-03-27T11:11:52Z
dc.date.issued2021
dc.description.abstractThere is an unmet clinical need for eye drop formulations to efficiently treat the diseases of the posterior ocular segment by non-invasive topical administration. Here, we systematically reviewed the literature on ocular penetration enhancers and their ability to transfer drugs to the posterior segment of the eye in experimental studies. Our aim was to assess which penetration enhancer is the most efficient at delivering drugs to the posterior segment of the eye, when topically applied. We conducted a comprehensive search in three electronic databases (Ovid Embase, Ovid MEDLINE, and PubMed) to identify all the relevant manuscripts reported on ocular penetration enhancers based on the PRISMA guidelines. We identified 6540 records from our primary database search and filtered them per our inclusion/exclusion criteria to select a final list of 14 articles for qualitative synthesis. Of these, 11 studies used cell penetrating peptides (CPPs), 2 used chitosan, and 1 used benzalkonium chloride (BAC) as the penetration enhancer. Cationic and amphipathic CPPs, transactivator of transcription (TAT), and penetratin can be inferred to be the best among all the identified penetration enhancers for drug delivery to the fundus oculi via topical eye drop instillation. Further high-quality experimental studies are required to ascertain their quantitative efficacygl
dc.description.peerreviewedSIgl
dc.description.sponsorshipThis project is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement N° 813440 (ORBITAL–Ocular Research by Integrated Training and Learning)gl
dc.identifier.citationPharmaceutics 2021, 13(2), 276gl
dc.identifier.doi10.3390/ pharmaceutics13020276
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10347/30388
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/813440-ORBITAL–Ocular Research by Integrated Training and Learninggl
dc.relation.publisherversionhttps://doi.org/10.3390/ pharmaceutics13020276gl
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses /by/4.0/)gl
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectTopical drug deliverygl
dc.subjectPenetration enhancersgl
dc.subjectNeuroprotectiongl
dc.subjectRetinagl
dc.subjectRetinal ganglion cellsgl
dc.subjectPosterior segmentgl
dc.subject.classificationMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320901 Análisis de medicamentosgl
dc.subject.classificationMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentosgl
dc.titlePenetration enhancers for topical drug delivery to the ocular posterior segment: a systematic Reviewgl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication44d6632e-65cd-485a-bb67-86df5567793a
relation.isAuthorOfPublication.latestForDiscovery44d6632e-65cd-485a-bb67-86df5567793a

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pharmaceutics 2021, 13, 276.pdf
Size:
888.96 KB
Format:
Adobe Portable Document Format
Description: